J Cancer 2020; 11(22):6491-6496. doi:10.7150/jca.45204 This issue

Research Paper

Improved diagnostic value by combining plasma PON1 level with tumor biomarkers in Colorectal Cancer patients

Jingdan Zhang1,2, Xiangling Yang1,2, Lili Wei1, Huiliu Tan1, Junxiong Chen1,2, Weiqian Li1,2, Kawo Chan1,2, Yixi Su1,2, Lu Zhao1, Suhua Hu1, Shuoxian Zhong1, Yanhong Xiao1✉, Huanliang Liu1,2✉

1. Department of Clinical Laboratory, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510655, China.
2. Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, Guangdong Institute of Gastroenterology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510655, China.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Zhang J, Yang X, Wei L, Tan H, Chen J, Li W, Chan K, Su Y, Zhao L, Hu S, Zhong S, Xiao Y, Liu H. Improved diagnostic value by combining plasma PON1 level with tumor biomarkers in Colorectal Cancer patients. J Cancer 2020; 11(22):6491-6496. doi:10.7150/jca.45204. Available from https://www.jcancer.org/v11p6491.htm

File import instruction

Abstract

The incidence of colorectal cancer (CRC) ranks third among all cancers in China and improvements in screening for CRC have an important impact on prevention and control of the disease. Paraoxonase 1 (PON1) is a calcium ion-dependent hydrolase that is widely distributed in tissue. Its diagnostic value in colorectal cancer has been reported, but the diagnostic value of combining PON1 with carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), carbohydrate antigen 12-5 (CA12-5) in colorectal cancer has not been evaluated. Experiments were carried out in a total of 284 CRC patients and 90 healthy controls. The primary cohort was randomly divided into training and validation sets. The levels of PON1 in plasma of CRC patients were significantly lower than that in the healthy controls (P < 0.001). It showed excellent diagnostic value with the AUC reaching 0.750 for the training set and 0.742 for the validation set. Furthermore, combining PON1 with CEA, CA12-5, CA19-9 could better classify CRC patients (AUC rising from 0.821, 0.716, 0.712 to 0.875, 0.817 and 0.814, respectively, in the training set, from 0.818, 0.581, 0.593 to 0.854, 0.770, and 0.772 in the validation set). In conclusion, PON1 can serve as a diagnostic biomarker for CRC and raise the sensitivity and specificity when incorporated with traditional tumor biomarkers.

Keywords: Paraoxonase 1, biomarker, colorectal cancer, diagnostic value